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C151 in KEAP1 is the main cysteine 
sensor for the cyanoenone class 
of NRF2 activators, irrespective of 
molecular size or shape
Sharadha Dayalan Naidu1, Aki Muramatsu2, Ryota Saito2, Soichiro Asami2, Tadashi Honda3, 
Tomonori Hosoya4, Ken Itoh4, Masayuki Yamamoto2, Takafumi Suzuki2 & Albena T.  
Dinkova-Kostova1,5
Numerous small molecules (termed inducers), many of which are electrophiles, upregulate 
cytoprotective responses and inhibit pro-inflammatory pathways by activating nuclear factor-erythroid 
2 p45-related factor 2 (NRF2). Key to NRF2 activation is the ability to chemically modifying critical 
sensor cysteines in the main negative regulator of NRF2, Kelch-like ECH-associated protein 1 (KEAP1), 
of which C151, C273 and C288 are best characterized. This study aimed to establish the requirement 
for these cysteine sensor(s) for the biological activities of the most potent NRF2 activators known to 
date, the cyclic cyanoenones, some of which are in clinical trials. It was found that C151 in KEAP1 is the 
main cysteine sensor for this class of inducers, irrespective of molecular size or shape. Furthermore, 
in primary macrophage cells expressing C151S mutant KEAP1, at low concentrations, the tricyclic 
cyanoenone TBE-31 is inactive as an activator of NRF2 as well as an inhibitor of lipopolysaccharide-
stimulated gene expression of the pro-inflammatory cytokines IL6 and IL1β. However, at high inducer 
concentrations, NRF2 activation proceeds in the absence of C151, albeit at a lower magnitude. Our 
findings highlight the intrinsic flexibility of KEAP1 and emphasize the critical importance of establishing 
the precise dose of NRF2 activators for maintaining on-target selectivity.
The KEAP1/NRF2/ARE pathway is at the forefront of cellular defense. Induction of this pathway is protective 
against various conditions of stress. Conversely, failure to upregulate the pathway leads to increased susceptibility 
and accelerated disease pathogenesis. Under basal conditions, transcription factor nuclear factor-erythroid 2 
p45-related factor 2 (NRF2) is targeted for ubiquitination and proteasomal degradation by a repressor protein 
Kelch-like ECH-associated protein 1 (KEAP1)1,2, a substrate adaptor for Cullin 3 (CUL3)-based E3 ubiquitin 
ligase3–5. Pharmacological inducers of the pathway chemically modify specific cysteine residues within KEAP1, 
leading to loss of repressor function, NRF2 accumulation and enhanced transcription of genes encoding a large 
network of cytoprotective proteins6–10. The NRF2 target genes contain specific regulatory sequences, termed 
antioxidant response elements (ARE) in their promoter/enhancer regions, to which NRF2 binds as a heterod-
imer with a small MAF transcription factor. The products of these genes control various antioxidant pathways 
such as glutathione (GSH) synthesis and regeneration [e.g. glutamate-cysteine ligase catalytic subunit (GCLC) 
and glutamate-cysteine ligase modifier subunit (GCLM)], GSH utilization [e.g. glutathione S-transferases 
(GST)], thioredoxin synthesis and regeneration [e.g. thioredoxin 1 (TXN1), thioredoxin reductase (TXNRD1) 
and peroxiredoxin 1 (PRDX1)] and NADPH production [e.g. glucose 6-phosphate dehydrogenase (G6PD), 
6-phosphogluconate dehydrogenase (PGD), malic enzyme (ME1), isocitrate dehydrogenase (IDH1)]. The 
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enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1), a highly inducible prototypic NRF2 target, is an NAD(P)
H-dependent flavoprotein with diverse cytoprotective activities11. NQO1 catalyzes the obligatory 2-electron 
reductions of quinones, thus preventing glutathione depletion and redox cycling.
The most prominent feature of the majority of small molecule NRF2 activators is their sulfhydryl reactivity. In 
1988, a decade before the discovery of NRF2, Paul Talalay and his colleagues recognized that many structurally 
diverse NQO1 inducers are Michael reaction acceptors characterized by olefinic (or acetylenic) bonds that are 
rendered electrophilic by conjugation with electron-withdrawing groups12. This was a breakthrough discovery 
as it identified a common feature of these seemingly unrelated compounds, and importantly, also made pos-
sible the prediction of chemical structures with potential inducer activity. To allow testing for new inducers, a 
highly quantitative and robust bioassay was developed which measures changes in the NQO1 enzyme activity 
in murine Hepa1c1c7 cells; the Concentration that Doubles the specific activity of NQO1 (CD value) provides 
a measure of inducer potency13. Using this assay, extremely high NQO1 inducer potency, with CD values in the 
low nanomolar concentration range, was reported for the semisynthetic triterpenoids, such as CDDO (2-cyano-
3,12-dioxooleana-1,9(11)-dien-28-oic acid, Fig. 1) and its analogs with cyanoenone functionalities as Michael 
acceptors14. These compounds were derived from a natural product, oleanolic acid (3-β-hydroxyolean-12-en-
28-oic acid) and initially identified as highly potent inhibitors of inducible nitric oxide synthase (iNOS)15–19. The 
introduction of the strongly electrophilic cyanoenone functionality into the oleanolic acid skeleton is considered 
to confer potent NRF2-inducing and anti-inflammatory activities. Currently, the methyl ester analog of CDDO 
(CDDO-Me, also known as bardoxolone methyl) is being evaluated in Phase II clinical trials for the treatment of 
pulmonary arterial hypertension (PAH) in the USA (NCT02036970, ClinicalTrials.gov) and diabetic nephropa-
thy in Japan (NCT02316821, ClinicalTrials.gov).
Subsequently, many tricyclic and monocyclic compounds containing cyanoenone functionalities were 
designed and synthesized, and their potencies were evaluated using the quantitative NQO1 bioassay in Hepa1c1c7 
cells. Among these derivatives, the acetylenic tricyclic bis(cyanoenone), (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8- 
trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile (TBE-31, Fig. 1) is the most 
potent inducer, active at low and even sub-nanomolar concentrations (CD = 0.9 nM)20–22. Both of the cyanoenone 
functionalities in rings A and C contribute to the inducer activity of TBE-31, and their simultaneous presence 
within a rigid three-ring system results in exceptionally high inducer potency23.
The cyanoenone inducers potently inhibit pro-inflammatory pathways. Thus, exposure to 1 nM of TBE-31 
suppresses nitric oxide (NO) production induced by interferon gamma (IFN-γ) in RAW 264.7 cells20,22. The 
oral administration of TBE-31 to rats protects them from aflatoxin-induced hepatocarcinogenesis by reducing 
the formation of DNA-aflatoxin adducts as well as the size and number of preneoplastic lesions20. This effect is 
mediated through the activation of NRF2 and the inhibition of pro-inflammatory pathways. This study suggests 
the potential use of TBE-31 as a chemotherapeutic and chemopreventive agent. The role of NRF2 as the mediator 
of the protective effects of TBE-31 against tumor development is further strengthened by the fact that genetic (by 
KEAP1 knockdown) or pharmacological (by small quantities of TBE-31, administered topically twice a week) 
activation of NRF2 reduces inflammation and photocarcinogenesis in the skin of SKH-1 hairless mice exposed to 
Figure 1. Selected cyanoenone NRF2 activators and their NQO1 inducer potencies (CD values) in Hepa1c1c7 
cells. Chemical structures of: 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), 2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid (CDDO-Im), (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-
dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile (TBE-31), 9a-ethynyl-3-oxo-9,9a-
dihydro-3H-fluorene-2-carbonitrile (MCE-23), and 3-ethynyl-3-methyl-6-oxocyclohexa-1,4-dienecarbonitrile 
(MCE-1).
www.nature.com/scientificreports/
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ultraviolet (UV) radiation24, and the protective effect of the KEAP1 knockdown is abrogated when NRF2 is defi-
cient25. At higher concentrations (in the sub-micromolar range), TBE-31 suppresses non-small cell lung cancer 
(NSCLC) cell migration and epithelial mesenchymal transition (EMT) by inhibiting TGFβ-dependent actin stress 
fiber formation and by directly binding to actin, inhibiting its polymerization26, suggesting the potential utility 
of TBE-31 in metastatic disease. Most recently, it was shown that oral administration of TBE-31 to wild type, but 
not NRF2-knockout mice that had been rendered obese and insulin resistant by consumption of high-fat and 
high-fructose diet, reversed insulin resistance, and attenuated obesity and liver disease27.
The tricyclic cyanoenone MCE-23 (9a-ethynyl-3-oxo-9,9a-dihydro-3H-fluorene-2-carbonitrile) (Fig. 1) 
shares ring C with TBE-31, but lacks the cyanoenone functionality in ring A, and is relatively less potent than 
TBE-31 as an NQO1 inducer (CD = 41 nM)28. The monocyclic cyanoenone MCE-1 (3-ethynyl-3-methyl-6-
oxocyclohexa-1,4-dienecarbonitrile) (Fig. 1), which represents ring C of TBE-31 and MCE-23, is also an 
NQO1 inducer (CD = 22 nM)23,29 and has a strong anti-inflammatory activity in RAW 264.7 cells and pri-
mary murine macrophage cells29. Both TBE-31 and MCE-1 have antidepressant effects in an animal model of 
inflammation-mediated depression30.
TBE-31 binds to KEAP1 covalently and reversibly23, and is suitable for chronic in vivo administration31. 
TBE-31, MCE-23 and MCE-1 are all highly reactive with sulfhydryl groups as they contain activated Michael 
acceptors within their structures. By use of the crystalline-sponge method, the crystal structure of the Michael 
adduct of MCE-23 with a small molecule thiol was determined32. In vitro, TBE-31 binds to KEAP1 cysteines23, 
but the specific sensor cysteine(s) has not been defined. A recent study has reported that KEAP1 C151 is required 
for NRF2 activation by a series of pentacyclic and tricyclic cyanoenones33. Whether C151 is also the sensor for 
TBE-31, MCE-23, or MCE-1 is currently unknown. In addition to C151, which is located in the BTB domain 
of KEAP1, C273 and C288 located in the intervening region, are well-recognized sensor cysteines34–37. In the 
current study, using KEAP1-knockout (KKO) mouse embryonic fibroblast (MEF) cells rescued with wild-type 
(WT) or cysteine mutants of KEAP1 and primary macrophages isolated from KEAP1-wild type (KEAP1+/+) 
or KEAP1-C151S-mutant (KEAP1C151S/C151S) mice, and TBE-31, MCE-23, and MCE-1 as model cyanoenones, 
we established that C151 is the main cysteine sensor for the cyanoenone class of inducers, irrespective of their 
molecular size or shape, and further uncovered a previously unrecognized flexibility in the sensing mechanism. 
Moreover, in primary macrophage cells expressing C151S mutant KEAP1, at low inducer concentrations, the 
tricyclic cyanoenone TBE-31 is inactive not only as an inducer of the classical NRF2 target NQO1, but also as 
an inhibitor of lipopolysaccharide-stimulated gene expression of the pro-inflammatory cytokines interleukin 6 
(IL6) and interleukin IL1β (IL1β). To our knowledge, this is the first demonstration for the requirement of C151 
in KEAP1 for the inhibition of pro-inflammatory gene expression by an NRF2 activator.
Results
Cysteine 151 in KEAP1 is the primary sensor for the cyanoenone inducers in MEF cells. Early 
mutagenesis studies showed that mutants of KEAP1, in which C273 and/or C288 were substituted with either 
serine or alanine, were inactive in repressing NRF2, rendering the transcription factor constitutively active35,36,38. 
To test whether these cysteines serve as inducer sensors in cells, it was necessary to identify amino acid sub-
stitutions, which preserve the repressor function of KEAP1. Using a systematic approach whereby C273 and/
or C288 were substituted with each of the natural amino acids, it was found that C273W and C288E mutations 
do not affect the ability of KEAP1 to repress NRF239. With this information in hand, a new experimental sys-
tem was developed based on the introduction of an expression vector encoding hemagglutinin (HA)-tagged 
murine KEAP1 ligated to the PiggyBac transposon system39. Expression plasmids encoding wild-type (WT) or 
cysteine(s) mutant HA-KEAP1 were transfected into KKO MEF cells, and various stable HA-KEAP1 expressing 
lines were established. Using this system, it was found that the semisynthetic triterpenoid CDDO-imidazolide 
[CDDO-Im, 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole)] (Fig. 1)17 and the closely related com-
pound, RTA-408, required C151 for their ability to cause NRF2 stabilization39,40, implicating C151 as the sensor 
cysteine for these pentacyclic cyanoenones.
The tricyclic cyanoenone TBE-31 shares its ring A with the pentacyclic CDDO-Im, but the two compounds 
differ in size (Fig. 1). To test whether the smaller TBE-31 is sensed by the same or different cysteine(s) in KEAP1, 
which senses the pentacyclic CDDO-Im and RTA-408, KKO MEF cells stably expressing HA-tagged WT KEAP1 
(termed WT-KKO) or its cysteine mutants, namely C151S-KKO, C273W/C288E-KKO, or C151S/C273W/
C288E-KKO, were exposed to TBE-31 (10 or 50 nM) for 3 h, and the levels of NRF2 were determined in whole cell 
lysates by immunoblotting. Because inactivation of KEAP1 leads to NRF2 stabilization, the levels of NRF2 serve 
as a sensitive readout for KEAP1 activity. An antibody against HA was used to report on the uniformity of the 
expression levels of WT KEAP1 and its cysteine mutants. In the WT-KKO or the double cysteine mutant C273W/
C288E-KKO MEF cells, NRF2 accumulated upon treatment with TBE-31 (Fig. 2A,B). In contrast, under identical 
experimental conditions, NRF2 did not accumulate in KKO MEF cells harboring the single KEAP1 mutant C151S 
or the triple KEAP1 mutant C151S/C273W/C288E (Fig. 2A,B). These results show that, similar to the pentacyclic 
cyanoenones CDDO-Im and RTA-408, C151 is the primary sensor in KEAP1 for the tricyclic TBE-31.
To determine the cysteine sensor(s) of KEAP1 for MCE-23, which in contrast to TBE-31 has only one reac-
tive center, and for MCE-1, which has the smallest size in this cyanoenone set of compounds, KEAP1 KO MEFs 
rescued with either WT or cysteine mutants of KEAP1, were treated with MCE-23 or MCE-1 for 3 h. In the 
WT-KKO and the double mutant C273/C288-KKO MEF cells, treatment with either compound caused NRF2 
accumulation in a dose-dependent manner (Fig. 3A,B). However, treatment of the single mutant C151S-KKO 
or the triple mutant C151S/C273W/C288E-KKO MEF cells with MCE-23 or MCE-1 failed to upregulate NRF2, 
indicating that, similar to the bis(cyanoenone) TBE-31, C151 is the primary sensor in KEAP1 for the cyanoe-
nones MCE-23 and MCE-1. Together with our previous findings, these results show that a pentacyclic com-
pound like CDDO-Im can be reduced in size to a tricyclic compound, such as TBE-31 or MCE-23, which can be 
www.nature.com/scientificreports/
4SCIeNTIfIC RepoRts |  (2018) 8:8037  | DOI:10.1038/s41598-018-26269-9
further reduced in size to a monocyclic compound like MCE-1, and still retain specificity for the same cysteine 
sensor in KEAP1, C151. These results further imply that preserving the reactive cyanoenone center is sufficient 
to confer specificity, and that chemical reactivity (rather than shape or size) is the most important feature of the 
Figure 2. C151 in KEAP1 is the primary sensor for TBE-31 in MEF cells. Western blot analyses of total cell 
lysates of KEAP1-knockout MEF cells rescued with either wild-type (WT) (A,B), single cysteine mutant C151S 
(A), double cysteine mutant C273W/C288E (B), or triple cysteine mutant C151S/C273W/C288E (A and B) 
of mouse N-terminally tagged HA-KEAP1. Cells (3 × 105 per well), growing in 6-well plates, were exposed to 
vehicle (0.1% DMSO) or TBE-31 for 3 h, after which the cells were lysed. Immunoblotting was performed on 
cell lysates using antibodies raised against NRF2, HA and α-tubulin.
Figure 3. C151 in KEAP1 is the primary sensor for MCE-23 and MCE-1 in MEF cells. Western blot analyses 
of total cell lysates of KEAP1-knockout MEF cells rescued with either wild-type (WT), single cysteine mutant 
C151S, double cysteine mutant C273W/C288E or triple cysteine mutant C151S/C273W/C288E of mouse 
N-terminally tagged HA- KEAP1. Cells (3 × 105 per well), growing in 6-well plates, were exposed to vehicle 
(0.1% DMSO) (A,B), MCE-23 (A) or MCE-1 (B) for 3 h, after which the cells were lysed. Immunoblotting was 
performed on cell lysates using antibodies raised against NRF2, HA and α-tubulin.
www.nature.com/scientificreports/
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cyanoenone inducers. These conclusions are supported by data from two recent crystallographic studies. Thus, 
the crystal structure of the BTB domain of KEAP1 in complex with CDDO was solved41, showing that CDDO 
occupies a shallow groove containing C151, which becomes deeper and more defined upon compound binding. 
This is in agreement with the recently determined crystal structures of BTB KEAP1 in complex with a tricyclic 
cyanoenone pyrimidine derivative (TX64014) and of BTB KEAP1 in complex with a tricyclic cyanoenone pyra-
zole derivative (TX64063)33, which share the same cyanoenone function in ring A with the cyanoenones exam-
ined in the current study.
Cysteine 151 in KEAP1 is the primary sensor for the cyanoenone inducers in primary peritoneal 
macrophages. To confirm that our conclusion that C151 is the primary sensor cysteine in KEAP1 for the 
cyanoenones is not limited to MEF cells, we next isolated primary peritoneal macrophages (PMϕ) from WT 
(KEAP1+/+) and KEAP1C151S/C151S mutant mice, and exposed these cells to a range of concentrations (15, 30, 
60 or 120 nM) of TBE-31 for 3 h. In the primary WT PMϕ cells, NRF2 accumulation was observed at all of the 
tested concentrations of TBE-31 (Fig. 4A). In contrast, in the primary KEAP1C151S/C151S PMϕ cells, NRF2 did not 
accumulate when the cells were exposed to lower concentrations (15, 30 or 60 nM) of TBE-31 (Fig. 4A). Similar 
results were obtained after a 3-h exposure to 12.5 or 25 nM of MCE-1 (Fig. 4B). These findings confirm that C151 
in KEAP1 is required for NRF2 stabilization by both the tricyclic and the monocyclic cyanoenones. Surprisingly, 
however, exposure to 120 nM TBE-31 (the highest concentration tested) was able to cause stabilization of NRF2 
in both WT and KEAP1C151S/C151S PMϕ cells. Together, these results suggest that although C151 is the primary 
sensor cysteine for TBE-31, when in excess, the inducer is able to also affect other cysteines of KEAP1, and con-
sequently lead to NRF2 activation. Alternatively, it is possible that at high inducer concentrations, TBE-31 causes 
NRF2 stabilization by inactivating the KEAP1-independent glycogen synthase kinase-3 (GSK3)/β-transducin 
repeat-containing protein (β-TrCP)-mediated degradation of NRF242–44. However, this is unlikely to occur under 
our experimental conditions where GSK3 is constitutively phosphorylated (and therefore maintained inactive) 
due to the growth factors present in the cell culture medium.
Cysteine 151 in KEAP1 is required for induction of NRF2-mediated transcription by low, but 
not high concentrations of TBE-31. It has been shown previously that TBE-31 is a potent and robust 
inducer of the NRF2-transcriptional target heme oxygenase 1 (HO-1) in cells and in vivo20. Having confirmed the 
requirement for C151 of KEAP1 for stabilization of NRF2 by low (10 nM), but not high (100 nM) concentrations 
of TBE-31 (Fig. 5A), we next addressed the importance of this cysteine for NRF2-mediated transcription by use 
of a fluorescent reporter (DsRed) under the control of the promoter of HO-1 (HO-1DsRed/+) (Fig. 5B). Treatment 
with TBE-31 (10 nM) of KEAP1-WT, but not KEAP1C151S/C151S or NRF2-knockout (NRF2−/−), cells transfected 
with this reporter led to an increase in fluorescence intensity (Fig. 5C). A detailed dose-response experiment 
with quantification of the fluorescence intensity further confirmed the requirement for C151 for induction of 
NRF2-mediated transcription by TBE-31 concentrations up to 10 nM (Fig. 5D). However, although to a lower 
magnitude, induction in the absence of C151 was evident at a concentration of TBE-31 of 30 nM (Fig. 5D). These 
experiments show that, at low inducer concentration, C151 is critical for NRF2 transcriptional activity, but at high 
inducer concentrations, NRF2 activation can still proceed in the absence of C151.
Cysteine 151 in KEAP1 is required for the ability of TBE-31 to suppress the LPS-mediated 
transcriptional activation of interleukin 6 (IL6) and interleukin 1β (IL1β) in primary peritoneal 
macrophage cells. Early studies revealed that there is a linear correlation spanning more than 6 orders of 
magnitude of concentrations between the ability of cyanoenone NRF2 activators to induce NQO1 and to inhibit 
transcription of pro-inflammatory genes, such as inducible nitric oxide synthase (iNOS)14. It was later found 
Figure 4. C151 in KEAP1 is the primary sensor for TBE-31 in primary murine peritoneal macrophages. 
Western blot analysis performed on total cell lysates of primary peritoneal macrophages (106 cells), isolated 
from WT or KEAP1C151S/C151S mice, that had been treated with vehicle (0.1% DMSO) (A,B), TBE-31 (A) or 
MCE-1 (B) for 3 h. Antibodies raised against NRF2 and KEAP1 were used for detection.
www.nature.com/scientificreports/
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that this correlation is valid for NRF2 activators of various chemical classes45, implicating NRF2 as the mediator 
not only for the activation of cytoprotective genes, but also for the inhibition of pro-inflammatory responses. 
Multiple mechanisms underlie the ability of NRF2 to inhibit the activation of pro-inflammatory genes. An inverse 
correlation between NRF2 and NF-κB signaling has been observed in numerous experimental systems27,46–49. 
NRF2 activation has been shown to limit the type I interferon response50,51. Chromatin immunoprecipitation 
(ChIP)-seq and ChIP-qPCR analyses have revealed that, in macrophage cells stimulated with lipopolysaccharide 
(LPS), NRF2 binds to the proximity of the genes encoding IL6 and IL1β, and inhibits the recruitment of RNA 
Pol II, without affecting the recruitment of the pro-inflammatory transcription factors NF-κB p65 or C/EBPβ52. 
We have previously shown that TBE-31 protects SKH-1 hairless mice against inflammation caused by exposure 
to solar-simulated UV radiation, in part by inhibiting the transcription of pro-inflammatory genes, such as IL6 
and IL1β in the skin of these mice24. We therefore next asked whether C151 in KEAP1 was required for the 
Figure 5. At low inducer concentrations, C151 in KEAP1 is required for the ability of TBE-31 to activate 
expression of the HO-1 DsRed reporter in primary murine peritoneal macrophages. (A) NRF2 levels in total 
cell lysates of primary peritoneal macrophages isolated from WT or KEAP1C151S/C151S mice, that had been 
treated with vehicle (0.1% DMSO) or TBE-31 for 3 h. (B) Strategy for generating the HO-1DsRed/+ reporter mice. 
Deletion of the floxed region from the mouse Hmox1 flox allele by the Cre recombinase resulted in generation of 
the DsRed allele, in which the 3rd to 5th exons encoding an essential domain for the HO-1 activity are deleted, 
resulting in the expression of a DsRed fusion protein containing the N-terminal 48 amino acids of the HO-1 
protein. (C) Representative fluorescence microscopy images of primary peritoneal macrophages isolated from 
WT-, KEAP1C151S/C151S- or NRF2−/−HO-1DsRed/+ reporter mice, that had been treated with vehicle (0.1% DMSO) 
or 10 nM TBE-31 for 24 h. Scale bar, 100 µm. (D) Quantification of the fluorescence of DsRed in primary 
peritoneal macrophages (n = 4) isolated from mice of the three genotypes following a 24 h-treatment with 
increasing concentrations of TBE-31. *p < 0.05.
www.nature.com/scientificreports/
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ability of TBE-31 to inhibit the gene expression of IL6 and IL1β. PMϕ cells isolated from WT (KEAP1+/+) or 
KEAP1C151S/C151S mutant mice were challenged with LPS (1 ng/ml) with or without TBE-31 (10 nM) for 4 h. In 
full agreement with the data for the protein levels of NRF2 (Figs 4A and 5A), NRF2 transcriptional activation (as 
evidenced by the increase in the mRNA levels for NQO1) by TBE-31 only occurred in the KEAP1+/+, but not 
in the KEAP1C151S/C151S PMϕ cells (Fig. 6A). Compared to KEAP1+/+ cells, the TBE-31-mediated upregulation 
of the mRNA levels for HO-1, which is transcriptionally regulated by multiple mechanisms53, including acti-
vation of NRF2, was substantially diminished, although not fully abolished in the KEAP1C151S/C151S PMϕ cells 
(Fig. 6B). Furthermore, the LPS-mediated transcriptional activation of IL6 and IL1β was suppressed by TBE-31 
Figure 6. C151 in KEAP1 is required for the ability of TBE-31 to inhibit the gene expression of IL6 and IL1β 
in primary murine peritoneal macrophages challenged with LPS. mRNA levels for NQO1 (A), HO-1 (B), IL6 
(C) and IL1β (D) in peritoneal macrophages isolated from WT (KEAP1+/+) (n = 7) or KEAP1C151S/C151S (n = 11) 
mice, that had been treated ex vivo with LPS (1 ng/ml) and/or TBE-31 (10 nM) for 4 h. *p < 0.05.
www.nature.com/scientificreports/
8SCIeNTIfIC RepoRts |  (2018) 8:8037  | DOI:10.1038/s41598-018-26269-9
in KEAP1+/+ PMϕ cells, but not in their KEAP1C151S/C151S counterparts (Fig. 6C,D). The requirement for C151 
in KEAP1 for the ability of TBE-31 to suppress the LPS-mediated transcriptional activation of IL6 was further 
confirmed using PMϕ cells isolated from KEAP1+/+ and KEAP1C151S/C151S transgenic mice expressing the human 
IL6-luciferase (hIL6-BAC-Luc) reporter (Fig. 7A,B). Together, these results show that in macrophage cells, at low 
inducer concentrations, the anti-inflammatory activity of TBE-31 is due to its reactivity with C151 of KEAP1.
Discussion
In this study, we show that C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of inducers, 
irrespective of their molecular size or shape. Moreover, we found that C151 in KEAP1 is required not only for the 
activity of the tricyclic cyanoenone TBE-31 as an inducer of cytoprotective gene expression, but also as a suppres-
sor of pro-inflammatory responses.
The prevailing view is that KEAP1 is equipped with discreet sensor cysteines, each of which responds to 
defined types of inducers to trigger NRF2-dependent cytoprotective responses. Here, we found that the concen-
tration of electrophilic cyanoenone NRF2 activators is a critical determinant of their selectivity for the cysteine 
sensors in KEAP1. Thus, we have identified that, in addition to specificity, there is also flexibility in the sensing 
mechanism. Our findings have a number of implications. Firstly, they demonstrate the specificity of the sensing 
mechanism by establishing that C151 is the sensor cysteine in KEAP1 for all of the cyanoenones, irrespective of 
their shape or size. It is remarkable that a 5-ring compound, such as CDDO-Im, can be reduced in size to a 3-ring 
compound, such as TBE-31, which can be further reduced in size to a 1-ring compound, such as MCE-1, and 
still maintain specificity for the same cysteine sensor and consequently, inducer activity. Thus, the cyanoenone 
functionality is necessary and sufficient for inducer activity. However, other properties of the small molecule 
play roles in determining inducer potency, such as electron affinity54 and enantiospecificity21,33, and should be 
considered in drug design.
Secondly, our findings highlight the intrinsic flexibility and the critical importance of KEAP1 as the principal 
sensor protein for electrophiles and oxidants: although different specific cysteine sensors have evolved to respond 
to inducers of different types35,37,39,55, there is redundancy among the sensors, which allows the “electrophilic 
Figure 7. C151 in KEAP1 is required for the ability of TBE-31 to inhibit human IL6-luciferase reporter 
gene expression in primary murine peritoneal macrophages challenged with LPS. (A) Primary peritoneal 
macrophages were isolated from KEAP1+/+::hIL6-Luc or KEAP1C151S/C151S::hIL6-Luc mice and the cells (n = 3) 
were treated ex vivo with LPS (1 ng/ml) and/or TBE-31 (10 nM) for 4 h. (A) The luciferase reporter activity was 
determined in total cell lysates. *p < 0.05.
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counterattack response”56 to proceed even in the event of loss-of-function mutation(s) of specific KEAP1 sen-
sor(s). Such flexibility is extremely important, particularly when the levels of the electrophilic stressor(s) are high, 
and will prevent glutathione depletion and the ensuing oxidative stress, ensuring cell survival.
Thirdly, our findings explain some experimental results, which at first glance, may be viewed as discrepancies. 
Thus, it has been reported that stabilization of NRF2 by CDDO-Im (100 nM) is C151-independent55, whereas as 
stated above, in a recent study39 we have observed the absolute requirement for C151 in KEAP1 for the CDDO-Im 
(10 nM)-mediated NRF2 stabilization. Although both studies included an overlapping (30 nM) concentration 
of the compound, the 10-fold difference in the second concentration of CDDO-Im used in these experiments 
provides a plausible explanation for these seemingly different conclusions. This redundancy in the sensing mech-
anism can also explain the finding that in vitro, when present at a large (100-fold) stoichiometric excess, CDDO 
is still able to inhibit the binding of CUL3 to the BTB domain (amino acids 35–235) of KEAP1 bearing a C151S 
mutation, whereas only 3.3-fold excess is required to achieve the same degree of inhibition (~60%) for the bind-
ing of CUL3 to the WT BTB-KEAP1 protein41. An excess of inducer in comparison to the main sensor cysteine 
can also explain the observed partial stabilization of NRF2 and induction of NQO1 in cultured MEF cells from 
KEAP1−/−::TgKEAP1C151S mutant mice by tert-butylhydroquinone (tBHQ)57, for which C151 is the main sensor 
cysteine in KEAP135,37,39,55.
Fourthly, and perhaps most importantly with regard to potential clinical applications, our findings empha-
size the critical importance of establishing the precise dose of even the most selective NRF2 activators, such 
as the cyclic cyanoenones, for maintaining on-target selectivity. Dose precision is of outmost importance for 
these electrophilic NRF2 activators as such compounds have multiple cellular targets, which become affected in 
a dose-dependent manner. Thus, CDDO-Im, tBHQ, and guggulsterone have been shown to cause NRF2 stabi-
lization by inhibiting the phosphatase and tensin homolog deleted on chromosome 10 (PTEN), leading to the 
activation of the phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB)/AKT signaling, phosphorylation of 
GSK3, and consequently inactivation of the KEAP1-independent GSK3/β- TrCP-mediated degradation of the 
transcription factor58–60. However, this activity does not occur in the presence of growth factor signaling (when 
GSK3 is phosphorylated and inactive), and requires much higher concentrations of the inducers than those used 
in our study. Nonetheless, the electrophilic nature of these compounds provides an opportunity for interactions 
with the cysteine proteome that could affect multiple signaling pathways, such as those regulated by peroxisome 
proliferator-activated receptor γ (PARPγ), inhibitor of NF-κB kinase (IKK), janus tyrosine kinase/signal trans-
ducer and activator of transcription (JAK/STAT), the mechanistic target of rapamycin (mTOR), the retinoic acid 
receptor (RAR), the estrogen receptor (ER), and the insulin receptor (IR)61. These effects might be particularly 
pronounced under oxidative stress conditions when the levels of reduced glutathione are low.
Materials and Methods
Materials. All reagents were of the highest purity available, purchased from common commercial suppliers. 
The cyanoenone compounds (±)-TBE-31, MCE-23, and MCE-1 were synthesized as described previously22,28,29.
Generation of stable KEAP1-knockout (KKO) KEAP1-rescued MEF cell lines. Immortalized 
KEAP1-knockout (KKO) MEF cells were grown in low glucose Dulbecco modified Eagle medium (Wako 
Chemical, Japan) supplemented with 9% fetal bovine serum (FBS) at 37 °C and 5% CO2. The PiggyBac transposon 
system (PB514B-2; System Biosciences, California, USA) was utilized to generate stable cell lines expressing HA 
(amino acid sequence: YPYDVPDYA)-tagged mouse KEAP1 (HA-KEAP1) or cysteine mutants of HA-KEAP1 by 
incorporating the cDNA encoding its protein sequence. KKO MEF cells were co-transfected with the PiggyBac 
expression vector and the plasmid encoding the transposase by electroporation with a double 1,100-V pulse for 
30 ms. Forty-eight to 72 h post-transfection, cells were selected with puromycin (2 mg/ml) for one week to 10 
days. The expression of red fluorescent protein (RFP) was used as a marker for HA-KEAP1 cDNA incorporation, 
and single colonies were isolated. These were expanded and tested for the relative expression of endogenous 
NRF2 and HA-KEAP1 by immunoblotting. For experiments, MEF cells (3 × 105) were plated in each well of a 6 
well plate, and 20 to 24 h later, the cells were exposed to either vehicle (0.1% DMSO) or the NRF2 activators for a 
further 3 h. Following treatment, the cells were subjected to immunoblotting analysis.
Generation of transgenic mice. All experiments involving animals were approved by the Tohoku 
University Animal Care Committee and were compliant with the regulations of The Standards for Human Care 
and Use of Laboratory Animals of Tohoku University (Sendai, Japan) and the Guidelines for Proper Conduct 
of Animal Experiments of the Ministry of Education, Culture, Sports, Science and Technology of Japan. 
hIL6-Luc mice were generated using a bacterial artificial chromosome (BAC) clone containing extended flanking 
sequences of the human interleukin 6 gene (IL6) locus, in which the luciferase (Luc) reporter gene is integrated 
as described62. The generation of mice expressing the fluorescent reporter DsRed under the control of the pro-
moter of the mouse Hmox1 gene (termed HO-1DsRed/+mice) will be described in detail elsewhere (manuscript in 
preparation). Stable KEAP1C151S/C151S knock-in mice were generated using the CRISPR/Cas9 technology. B6D2F1 
(C57BL6 × DBA2) super-ovulating female mice were mated with B6D2F1 males, and fertilized embryos were 
collected. A cocktail of guide RNA (nucleotide sequence: TGGGCGAGAAATGTGTCCTG), Cas9 mRNA, and 
the donor oligonucleotide were injected into the cytoplasm of fertilized embryos, which were maintained in M16 
mouse embryo medium placed in a 37 °C humidified incubator in 5% CO2 in air. Subsequently, 15 to 25 embryos 
were implanted into pseudo-pregnant ICR female mice. The mice containing the mutation on the Keap1 allele 
were crossed with WT C57BL6 mice to produce heterozygote animals. Mice that were confirmed heterozygotes 
were then crossed to produce KEAP1C151S/C151S mice. The KEAP1C151S/C151S mice, which were used in the experi-
ments were maintained for two generations by crossing with WT C57BL6 mice. Genotyping was performed by 
quantitative real-time PCR (Applied Biosystems). The WT control mice were of C57BL6 genetic background. 
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All information regarding the sequences of the guide RNA, targeting oligonucleotide, and genotyping primers, 
is available upon request. KEAP1C151S/C151S::HO-1DsRed/+ and KEAP1C151S/C151S::hIL6-Luc mice were generated by 
crossing KEAP1C151S/C151S mice with HO-1DsRed/+ mice and hIL6-Luc mice, respectively. NRF2−/−::HO-1DsRed/+ 
mice were generated by crossing NRF2−/−mice with HO-1DsRed/+ mice.
Isolation of peritoneal macrophage (PMϕ) cells. Mice received 2.0 ml of 4% thioglycolate solution, 
i.p. Four days later, the resulting fluid was extracted from the peritoneal cavity, immediately placed on ice and 
suspended in ice-cold RPMI 1640 medium without serum. The peritoneal macrophage (PMϕ) cells were washed 
and collected by centrifugation (400 × g for 10 min at 4 °C). The PMϕ cells were then resuspended in RPMI 1640 
medium supplemented with 10% FBS, counted, and plated in 6-well plates at a density of 106 cells per well, and 
placed in a 37 °C humidified incubator in 5% CO2 in air. Four hours later, when the PMϕ cells had adhered to 
the plates, they were washed twice with PBS before proceeding with treatments with the inducers as indicated in 
the figure legends. For the luciferase activity reporter assay, cells were lysed in passive lysis buffer (Promega), the 
luciferase substrate was added according to the manufacturer’s (Promega) instructions, and the enzyme activity 
was determined in cell lysates using Lumat LB 9507 tube luminometer (Berthold Technologies).
Real-time quantitative PCR analysis. RNA was isolated from cells using Sepazol-RNA I Super G RNA 
Extraction Kit (Nakalai), and cDNA was synthesized from the RNA using ReverTra Ace qPCR RT master mix 
with gRNA Remover (Toyobo). Real-time quantitative PCR was performed with QuantStudio 6 Real-time PCR 
System (Applied Biosystems) using THUNDERBIRD SYBR qPCR Mix (Toyobo) or THUNDERBIRD probe 
qPCR Mix (Toyobo). The primer sequences are listed in Table 1. The mRNA levels for each gene were normalized 
using hypoxanthine phosphoribosyltransferase (Hprt) as an internal control.
Immunoblotting. For immunoblotting analysis of the levels of NRF2 and KEAP1, cells were washed with 
PBS and lysed by adding to each well of a 6-well plate 200 µl of lysis buffer [100 mM Tris-HCl, pH 6.8; 4% (w/v) 
sodium dodecyl sulfate (SDS); 20% (v/v) glycerol; 0.001% (w/v) Bromophenol Blue] at room temperature. 
Following collection of the samples, the lysates were snap-frozen in liquid nitrogen and stored at −80 °C until 
they were ready to be processed for gel electrophoresis. The lysates were then thawed and subjected to sonication 
for 30 seconds and subsequently heated at 95 °C for 5 min. After cooling, dithiothreitol (DTT) was added to a final 
concentration of 20 mM, and the lysates were incubated with the reducing agent at 37 °C for 10 min. The protein 
concentration of each whole cell lysate was determined by using the BCA protein assay (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA), and 15–20 μg of total protein were used for the detection of NRF2, HA-KEAP1, 
KEAP1, and α-tubulin. Proteins were separated by electrophoresis on an 8% SDS–polyacrylamide gel using the 
BioRad gel electrophoresis system with SDS-running buffer [25 mM Tris-HCl, pH 7.4; 192 mM Glycine; and 0.1% 
(w/v) SDS], and then electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane using the 
Trans-Blot® Turbo™ transfer system (BioRad). After blocking with 10% non-fat milk at room temperature for 1 h 
or overnight at 4 °C, immunoblotting was performed using the following antibodies for either 1-2 h at room tem-
perature or overnight at 4 °C: rat monoclonal NRF2 antibody39 at a dilution of 1:100, rat monoclonal HA antibody 
(Roche, 3F10, California, USA) at a dilution of 1:1000, or rat monoclonal KEAP1 antibody39 at a dilution of 1:100. 
A mouse monoclonal antibody against α-tubulin (Sigma–Aldrich, DM1A, 1:5000-1:10000 dilution) was used as 
a loading control. In each case, the data are representative of two to three independent experiments.
Data analysis. All quantitative data are represented graphically and in the text as mean values ± 1 standard 
deviation (SD). Student’s t-test was used to test for statistical significance.
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